Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OPCON vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Opcon is a brand name for the injectable solution containing desmopressin acetate, a synthetic analog of the antidiuretic hormone vasopressin. It acts on V2 receptors in the renal collecting ducts to increase water reabsorption, reducing urine volume and osmolality.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Management of diabetes insipidus,Control of polyuria and polydipsia following traumatic or surgical head injury,Treatment of nocturnal enuresis in children (off-label),Treatment of hemophilia A and von Willebrand's disease (type I) to increase factor VIII and von Willebrand factor levels (off-label)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
IV: 2-4 mg bolus, may repeat every 5-10 minutes as needed; max total dose: 10 mg.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
The terminal elimination half-life is 8-12 hours in adults with normal renal function. This supports twice-daily dosing; half-life is prolonged in renal impairment.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Primarily metabolized in the liver by disulfide bond reduction and peptide cleavage. Not significantly metabolized by cytochrome P450 enzymes.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal elimination of unchanged drug accounts for approximately 65-70% of the administered dose; biliary/fecal excretion accounts for 20-25% following hepatic metabolism.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Approximately 80-85% bound to serum albumin and alpha-1-acid glycoprotein.
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Vd is approximately 1.5-2.0 L/kg, indicating extensive distribution into total body water and tissues.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Oral bioavailability is 85-90% due to minimal first-pass metabolism; intramuscular bioavailability is nearly 100%.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No dosage adjustment required for renal impairment.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
Child-Pugh Class A and B: No adjustment. Child-Pugh Class C: Use with caution; consider dose reduction by 50%.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
IV: 0.02-0.04 mg/kg/dose every 5-10 minutes as needed; max single dose: 0.1 mg/kg; max total dose: 2 mg.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Initiate at lower end of dosing range (e.g., 1-2 mg IV); titrate carefully due to increased sensitivity.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
WARNING: SEVERE HYPONATREMIA. Desmopressin can cause hyponatremia which may be life-threatening if severe and untreated. Risk is increased in patients with conditions predisposing to hyponatremia or those receiving certain medications. Monitor serum sodium levels, especially in the elderly, children, and patients with increased intracranial pressure.
None
Risk of severe hyponatremia and seizures; monitor fluid intake and serum sodium; use with caution in patients with fluid and electrolyte imbalances, renal impairment, cystic fibrosis, coronary artery disease, hypertension, and in the elderly; may increase blood pressure; avoid in patients with nephrotic syndrome or nephropathy; use with caution in patients receiving drugs that increase diuresis or thirst.
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hypersensitivity to desmopressin or any component; moderate to severe renal impairment (e GFR < 50 m L/min/1.73 m²); hyponatremia or propensity for hyponatremia; primary nocturnal enuresis in patients with uncontrolled hypertension or history of electrolyte disturbances; von Willebrand's disease type IIB (off-label use)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No specific food interactions. Avoid alcohol as it may increase dizziness or drowsiness.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Pregnancy Category C. First trimester: potential risk of congenital anomalies based on animal data; second and third trimesters: risk of fetal hypoxia and bradycardia due to uterine hypertonus.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Excreted in human milk in low concentrations; M/P ratio approximately 0.6. Use with caution due to potential for adverse effects in nursing infants.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
No standard dose adjustment recommended; however, increased clearance in pregnancy may require higher doses to achieve therapeutic effect. Titrate based on clinical response and maternal-fetal monitoring.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
OPCON is a brand name for oxymetazoline, an α-adrenergic agonist used topically for nasal congestion. Avoid use beyond 3 days to prevent rhinitis medicamentosa. Contraindicated in narrow-angle glaucoma and after transsphenoidal hypophysectomy. Monitor for rebound congestion.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Do not use for more than 3 days to avoid worsening congestion.,Spray once into each nostril twice daily as needed.,Avoid contact with eyes; rinse with water if contact occurs.,Do not share the bottle to prevent infection.,Consult a doctor if symptoms persist beyond 3 days.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OPCON vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
OPCON is a Ophthalmic Decongestant (Vasoconstrictor) that works by Opcon is a brand name for the injectable solution containing desmopressin acetate, a synthetic analog of the antidiuretic hormone vasopressin. It acts on V2 receptors in the renal collecting ducts to increase water reabsorption, reducing urine volume and osmolality.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OPCON and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OPCON is: IV: 2-4 mg bolus, may repeat every 5-10 minutes as needed; max total dose: 10 mg.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OPCON and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OPCON is classified as Category C. Pregnancy Category C. First trimester: potential risk of congenital anomalies based on animal data; second and third trimesters: risk of fetal hypoxia and bradycardia due to uterin. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.